New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 19, 2013
08:43 EDTPPHMPeregrine updates top-line data from Phase 2 clinical trial of Bavituximab
Peregrine Pharmaceuticals reported data from its randomized, double-blind placebo-controlled Phase II trial of bavituximab in patients with second-line non-small cell lung cancer, or NSCLC. Data from the trial has been updated based on completion of an earlier review of discrepancies in the trial and the most current survival data from the trial. Updated results from this Phase II trial indicate a meaningful improvement in median overall survival of 11.7 months in the 3mg/kg bavituximab + docetaxel arm compared to 7.3 months in the control arm. Persistent separation in the survival curves was observed with response rates and progression free survival also favoring the 3mg/kg bavituximab + docetaxel arm in this difficult to treat second-line NSCLC. The results also demonstrated that bavituximab was well-tolerated with no significant differences in adverse events between the trial arms. Peregrine plans to report additional data from the trial, including updated subgroup analysis and safety data, at an upcoming scientific meeting.
News For PPHM From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
June 25, 2015
08:40 EDTPPHMPeregrine granted keu EU patent for bavituximab
Peregrine Pharmaceuticals announced that the European Patent Office, or EPO, has granted Patent Number 2,269,656, titled "Selected Antibodies Binding to Aminophospholipids and their Use in Treatment, Such as Cancer”. This important patent covers bavituximab as a composition of matter and for use in treating cancer including in combination with radiotherapy or chemotherapy, such as with docetaxel. The new patent covers bavituximab as a composition of matter, a range of related antibodies, including humanized and chain-shuffled antibodies and other sequence variations and their broad use in any diagnosis or therapy. The new patent also covers antibody drug conjugates, diagnostic and imaging constructs, liposomal and pharmaceutical combinations of bavituximab and related antibodies.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use